Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: PER

Olive Bolsters Leadership Team, Adds Cybernetics Division


U.S.A., Oct. 15, 2020 /PRNewswire/ -- The American Hospital Association estimates that hospitals and health systems will experience an additional $120.5 billion in financial losses through the end of 2020. Leaders report prioritizing technology development over physical growth in order to streamline operations and support employees, in turn mitigating operational pressure and financial uncertainty. In response to this demand, Olive today announced the expansion of its cybernetics division and continued company growth.

Olive has appointed three new executives to lead further cybernetic development of the company's AI workforce: Rohan D'Souza, Mike Biselli and Tony Brancato. Their expertise will drive further expansion and development of Olive's AI workforce, which currently supports more than 600 hospitals across the country. Olive's team has grown to more than 360 employees this year.

The announcement comes on the heels of news that digital health has experienced record-breaking funding in 2020. Olive has seen massive growth and momentum, becoming a critical infrastructure piece for hospitals and health systems. Olive Helps, a new platform that leverages cybernetics to help healthcare employees work faster and smarter, was announced this week. In September, the company reached a landmark $157MM in funding across multiple rounds this year, and also announced a mission-critical application of their AI workforce to support COVID-19 testing at Tufts Medical Center.

Olive's cybernetics division will support the adoption of Olive Helps across the company's customers in 2021:

"We are excited to welcome Rohan, Mike and Tony to the team as we build our company's cybernetics division and create new innovations to address the needs of tomorrow's health systems," said Sean Lane, CEO of Olive. "They are instrumental as we continue to help healthcare employees work smarter and faster on the front lines of patient care."

To learn more about Olive Helps and to schedule a demo, visit www.olivehelps.com.

About Olive
Olive's AI workforce was built specifically for healthcare, automating high-volume tasks and workflows to make healthcare more efficient, more affordable and more effective. Olive's unparalleled wisdom across healthcare allows her to shine a new light on the broken processes that stand between providers and exceptional patient care. Olive draws on this wisdom to find new opportunities to improve healthcare ? uncovering waste, tracking down efficiencies, and highlighting human potential with AI. She's all about improving healthcare operations today, so industry leaders can reinvent the future of healthcare tomorrow. To learn more about Olive, visit oliveai.com.

Media Contact:
Rachel Forsyth
[email protected]

SOURCE Olive


These press releases may also interest you

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...



News published on and distributed by: